Distribuzione geografica
Continente #
EU - Europa 5.240
NA - Nord America 4.896
AS - Asia 808
AF - Africa 267
SA - Sud America 21
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.237
Nazione #
US - Stati Uniti d'America 4.778
DE - Germania 2.058
SE - Svezia 840
IT - Italia 802
AT - Austria 443
CN - Cina 430
GB - Regno Unito 430
BG - Bulgaria 280
CI - Costa d'Avorio 154
CA - Canada 114
SN - Senegal 107
RU - Federazione Russa 106
VN - Vietnam 103
TR - Turchia 83
SG - Singapore 77
UA - Ucraina 73
FI - Finlandia 57
IN - India 49
BE - Belgio 47
CH - Svizzera 32
FR - Francia 20
NL - Olanda 12
JP - Giappone 11
HK - Hong Kong 9
PL - Polonia 9
IL - Israele 7
KR - Corea 7
CL - Cile 6
PH - Filippine 6
TW - Taiwan 6
GR - Grecia 5
ID - Indonesia 5
IE - Irlanda 5
BR - Brasile 4
RO - Romania 4
AR - Argentina 3
AU - Australia 3
AZ - Azerbaigian 3
EC - Ecuador 3
IR - Iran 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
VE - Venezuela 3
BY - Bielorussia 2
EG - Egitto 2
HU - Ungheria 2
MX - Messico 2
MY - Malesia 2
SV - El Salvador 2
TH - Thailandia 2
A1 - Anonimo 1
CO - Colombia 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DZ - Algeria 1
ES - Italia 1
EU - Europa 1
GE - Georgia 1
HR - Croazia 1
IS - Islanda 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MA - Marocco 1
MN - Mongolia 1
NG - Nigeria 1
NO - Norvegia 1
PE - Perù 1
PT - Portogallo 1
SA - Arabia Saudita 1
ZA - Sudafrica 1
Totale 11.237
Città #
Woodbridge 671
Chandler 602
Fairfield 524
Ann Arbor 425
Vienna 369
Houston 336
Sofia 280
Milan 275
Wilmington 218
Seattle 217
Ashburn 190
Cambridge 188
Beijing 185
Abidjan 154
Princeton 141
Lawrence 109
Dakar 107
Ottawa 106
Serra 94
Jacksonville 91
Florence 89
London 89
Medford 81
Frankfurt am Main 59
Izmir 57
Nanjing 56
Bremen 54
Boulder 53
Des Moines 53
Dearborn 52
Dong Ket 51
Brussels 46
Pisa 39
San Diego 39
Redmond 35
Lancaster 28
Bern 27
Redwood City 25
Rome 21
Nanchang 20
Washington 19
Jiaxing 17
Kunming 14
Changsha 13
Jüchen 13
Düsseldorf 11
Guangzhou 11
Ningbo 11
Norwalk 11
Shenyang 11
Chiesina Uzzanese 10
Hefei 10
New York 10
Nürnberg 10
Kocaeli 9
Tianjin 9
Hebei 8
Phoenix 8
Scandicci 8
Zhengzhou 8
Chengdu 7
Hangzhou 7
Istanbul 7
Jinan 7
Los Angeles 7
Munich 7
Boardman 6
Chicago 6
Falls Church 6
Grafing 6
Shanghai 6
Wuhan 6
Dallas 5
Salt Lake City 5
Samsun 5
San Francisco 5
Edinburgh 4
Marseille 4
Santiago 4
Toronto 4
Yonkers 4
Amsterdam 3
Atakum 3
Bratislava 3
Civitanova Marche 3
Detroit 3
Dublin 3
Fuzhou 3
Genoa 3
Hanoi 3
Hatfield 3
Indiana 3
Manila 3
Montale 3
Orange 3
Palermo 3
Pian Camuno 3
Pistoia 3
San Martino In Strada 3
Seoul 3
Totale 6.652
Nome #
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 196
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 187
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 178
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 176
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients 166
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 166
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 163
Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland 157
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 150
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 150
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 150
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 149
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 148
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 147
null 145
Targeted Therapy in Thyroid Cancer: State of the Art 143
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 138
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 133
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal 131
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 130
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 130
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 130
RET point mutations in Thyroid Carcinoma 129
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 129
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 128
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients 122
null 122
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 122
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid 121
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 121
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 119
Il carcinoma tiroideo: nuove prospettive terapeutiche. 119
New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. 116
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 116
Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy 114
Thyroid consequences of the Chernobyl nuclear accident. 114
null 114
KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease 113
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 112
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 111
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. 110
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 110
Correlation between early and 24th hour 131-I uptake in post-surgical thyroid remnant evaluation 109
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 109
Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. 108
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 108
Role of Thyroglobulin, Neck Ultrasound, Thyroglobulin Antibodies Trend and Diagnostic Whole Body Scan in the Management of Differentiated Thyroid Cancer Patients with Persistent Thyroglobulin Antibodies 108
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 107
null 107
Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma 105
null 105
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 104
Advantages and disadvantages of prophylactic central compartment lymph node dissection for differentiated thyroid cancer: the first randomized controlled study from a single referral center. 103
null 103
The stage of differentiated thyroid cancer at diagnosis is significantly more advanced in children than in adolescent 102
In vitro studies of retnoic acid treatment of human anaplastic, poorly differentiated papillary, follicular and medullary thyroid cancer cell lines 102
Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma 102
Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment 99
Less than 2% of the low- and intermediate-risk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan 97
Thyroid incidentaloma 96
Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow up of differentiated thyroid cancer patients 94
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments 93
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 93
BRAFV600E mutation is an indipendent predictive prognostic factor for persistent/recurrent disease in low risk differentiated Thyroid cancer patients: a 5 year follow-up study. 92
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 91
Studi in vitro del trattamento con acido retinico di linee di carcinoma tiroideo umano anaplastico, poco differenziato, follicolare e midollare 89
null 86
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 86
null 84
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 84
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 83
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 81
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 78
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 78
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 74
Significato prognostico della mutazione di BRAF in pazienti affetti da carcinoma papillare della tiroide con follow-up di 20 anni. 73
Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. 71
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 71
null 70
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 70
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 69
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 63
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 62
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 60
Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma 60
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 59
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 58
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 57
Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo et al 56
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 55
null 54
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 53
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 52
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates 52
Non thyroidal second primary malignancies in differentiated thyroid cancer patients: is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence? 49
Totale 10.715
Categoria #
all - tutte 21.950
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.950

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.267 0 0 0 86 116 24 213 86 105 218 257 162
2019/20202.462 265 132 212 115 235 264 258 121 158 282 385 35
2020/2021938 158 41 146 29 50 84 50 55 60 83 48 134
2021/20221.344 34 46 22 102 294 177 37 56 70 72 91 343
2022/20232.680 290 407 208 194 218 254 86 213 513 38 212 47
2023/2024654 209 193 251 1 0 0 0 0 0 0 0 0
Totale 11.477